ADPT (Adaptive Biotechnologies) Days Payable : 47.13 (As of Sep. 2024)

View and export this data going back to 2019. Start your Free Trial

What is Adaptive Biotechnologies Days Payable?

Adaptive Biotechnologies's average Accounts Payable for the three months ended in Sep. 2024 was $8.6 Mil. Adaptive Biotechnologies's Cost of Goods Sold for the three months ended in Sep. 2024 was $16.7 Mil. Hence, Adaptive Biotechnologies's Days Payable for the three months ended in Sep. 2024 was 47.13.

The historical rank and industry rank for Adaptive Biotechnologies's Days Payable or its related term are showing as below:

ADPT' s Days Payable Range Over the Past 10 Years
Min: 24.22 Med: 38.17 Max: 62.29
Current: 44.94

During the past 8 years, Adaptive Biotechnologies's highest Days Payable was 62.29. The lowest was 24.22. And the median was 38.17.

ADPT's Days Payable is ranked worse than
73.16% of 708 companies
in the Biotechnology industry
Industry Median: 124.1 vs ADPT: 44.94

Adaptive Biotechnologies's Days Payable increased from Sep. 2023 (32.18) to Sep. 2024 (47.13). It may suggest that Adaptive Biotechnologies delayed paying its suppliers.

Adaptive Biotechnologies Days Payable Historical Data

The historical data trend for Adaptive Biotechnologies's Days Payable can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Adaptive Biotechnologies Days Payable Chart

Adaptive Biotechnologies Annual Data

Trend

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Dec24

Days Payable

Get a 7-Day Free Trial

62.29

24.22

35.90

38.17

37.94

Adaptive Biotechnologies Quarterly Data
	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24	Jun24	Sep24	Dec24
Days Payable	Get a 7-Day Free Trial															28.38	50.27	52.05	47.13	36.96

Competitive Comparison of Adaptive Biotechnologies's Days Payable

For the Biotechnology subindustry, Adaptive Biotechnologies's Days Payable, along with its competitors' market caps and Days Payable data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Adaptive Biotechnologies's Days Payable Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Adaptive Biotechnologies's Days Payable distribution charts can be found below:

* The bar in red indicates where Adaptive Biotechnologies's Days Payable falls into.

Adaptive Biotechnologies Days Payable Calculation

Days Payable indicates the number of days that the account payable relative to cost of goods sold the company has. An increase of Days Payable may suggest that the company delays paying its suppliers.

Adaptive Biotechnologies's Days Payable for the fiscal year that ended in Dec. 2023 is calculated as

	Days Payable (A: Dec. 2023 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (A: Dec. 2022 )	+	Accounts Payable (A: Dec. 2023 ))	/	count )	/	Cost of Goods Sold (A: Dec. 2023 )	*	Days in Period
=	( (8.084	+	7.719)	/	2 )	/	75.553	*	365
=	7.9015					/	75.553	*	365
=	38.17

Adaptive Biotechnologies's Days Payable for the quarter that ended in Sep. 2024 is calculated as:

	Days Payable (Q: Sep. 2024 )
=	Average Accounts Payable					/	Cost of Goods Sold	*	Days in Period
=	( (Accounts Payable (Q: Jun. 2024 )	+	Accounts Payable (Q: Sep. 2024 ))	/	count )	/	Cost of Goods Sold (Q: Sep. 2024 )	*	Days in Period
=	( (9.867	+	7.351)	/	2 )	/	16.667	*	365 / 4
=	8.609					/	16.667	*	365 / 4
=	47.13

Adaptive Biotechnologies Days Payable Related Terms

Thank you for viewing the detailed overview of Adaptive Biotechnologies's Days Payable provided by GuruFocus.com. Please click on the following links to see related term pages.

Adaptive Biotechnologies Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Adaptive Biotechnologies Corp (NAS:ADPT) » Definitions » Days Payable

Comparable Companies

Traded in Other Exchanges

1HM:Germany

Address

1165 Eastlake Avenue East, Seattle, WA, USA, 98109

Website

https://www.adaptivebiotech.com

Adaptive Biotechnologies Corp is a company advancing the field of immune-driven medicine by harnessing the inherent biology of the adaptive immune system to transform the diagnosis and treatment of disease. Its clinical diagnostic product, clonoSEQ, is test authorized by the FDA for the detection and monitoring of minimal residual disease (MRD) in patients with multiple myeloma (MM), B cell acute lymphoblastic leukemia (ALL) and chronic lymphocytic leukemia (CLL) and is also available as a CLIA-validated laboratory developed test (LDT) for patients with other lymphoid cancers, including diffuse large B-cell lymphoma (DLBCL).

Executives

Chad M Robins	director, officer: CEO and Chairman	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Kyle Piskel	officer: Principal Accounting Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Stacy L Taylor	officer: SVP and General Counsel	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVENUE E SUITE 200, SEATTLE WA 98102
Tycho Peterson	officer: Chief Financial Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1165 EASTLAKE AVE E, SEATTLE WA 98109
Sharon Benzeno	officer: Chief Commercial Ofc Imm Med	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Francis Lo	officer: Chief People Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Julie Rubinstein	officer: President	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Susan Bobulsky	officer: SVP, Diagnostics, clonoSEQ	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Nitin Sood	officer: Chief Commercial Officer, MRD	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
R Mark Adams	officer: Chief Operating Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Michelle Renee Griffin	director	19723 NE 65TH LANE, KIRKLAND WA 98033
Michael J Pellini	director	222 DUTTON MILL RD, WILLISTOWN PA 19380
Katey Einterz Owen	director	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Harlan S Robins	officer: Chief Scientific Officer	C/O ADAPTIVE BIOTECHNOLOGIES CORPORATION, 1551 EASTLAKE AVE E STE 200, SEATTLE WA 98102
Peter M Neupert	director	13920 SE EASTGATE WAY, STE 300, BELLEVUE WA 98005